Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

nd uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Revenue
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... team including DESY scientists has observed tiny quantum vortices ... in the journal Science that the exotic ... nanodroplets. It is the first time that the quantum ... of what is known as superfluid helium, have been ... expectations," says Andrey Vilesov of the University of Southern ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... SPRING, N.Y. , Aug. 21, 2014 /PRNewswire/ ... the launch of their Nutraceutical "TELO-20 for Dogs" ... and only Telomere-lengthening supplement in the world for ... ends of every chromosome in the body. A ... world,s leading experts in Telomere Science and Aging, ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... REYKJAVIK, Iceland, August 10 deCODE genetics,(Nasdaq: ... the,quarter ended June 30, 2009. A conference call to ... will be webcast live tomorrow,Tuesday, August 11, at 8:00am ... , The financial results presented ...
... BOZEN, Italy, August 10 , ... Health Robotics today announced that it has signed ... Robot. The,agreement enables McKesson to achieve its goal of safely, ... "We are very pleased to have ...
... 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... sale of approximately 2.28 million shares of its common stock ... stock for gross proceeds of approximately $15.0 million on August ... per unit (each unit consisting of one share and a ...
Cached Biology Technology:deCODE genetics Announces Second Quarter 2009 Financial Results 2deCODE genetics Announces Second Quarter 2009 Financial Results 3deCODE genetics Announces Second Quarter 2009 Financial Results 4deCODE genetics Announces Second Quarter 2009 Financial Results 5deCODE genetics Announces Second Quarter 2009 Financial Results 6deCODE genetics Announces Second Quarter 2009 Financial Results 7deCODE genetics Announces Second Quarter 2009 Financial Results 8deCODE genetics Announces Second Quarter 2009 Financial Results 9deCODE genetics Announces Second Quarter 2009 Financial Results 10McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3Oncothyreon announces closing of $15.0 million registered direct financing 2
(Date:8/22/2014)... the birds and the bees. But that old ... fertilized. The fertilization process for flowering plants is ... male and female reproductive cells. New research from ... Munich, and including Carnegie,s Wolf Frommer, David Ehrhardt, ... signaling process that guides flowering plant fertilization. It ...
(Date:8/21/2014)... darkness use a previously unknown process for harvesting energy ... by a Penn State University scientist has discovered. The ... improving plant growth, harvesting energy from the Sun, and ... Erie and other lakes worldwide. A paper describing the ... Express edition of the journal Science on ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... scientists will swarm to the Austin Convention Center from ... the Entomological Society of America. Members of the ... for a complimentary press pass by writing to ... Topics covered during the meeting will include bed bugs, ...
... significant problems facing the world,s marine environments. Yet in the ... tons of plastic litter enter the ocean each year. ... of Law,s Emmett Center on Climate Change and the Environment ... sources and impacts of plastic marine litter and offers domestic ...
... devoted to getting more Hispanics into the fields ... honored a scientist at the Energy Department,s National ... Technical Achievement Award. Santiago Carlos Grijalva is ... Center at the Energy Systems Integration Facility (ESIF), ...
Cached Biology News:UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 2UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 3NREL researcher honored with Hispanic STEM award 2NREL researcher honored with Hispanic STEM award 3
...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: